[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100183943":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":32,"centralContacts":11,"locations":37,"responsibleParty":51,"collaborators":11,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":11,"eligibilityCriteria":58,"healthyVolunteers":55,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":11,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":11,"overallStatus":71,"whyStopped":11,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Diphenhydramine(Benadryl)","PLACEBO_COMPARATOR",null,[13],"Drug: Diphenhydramine",{"label":15,"type":16,"description":11,"interventionNames":17},"Lidocaine","ACTIVE_COMPARATOR",[18],"Drug: Lidocaine",[20,26],{"type":21,"name":15,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Lidocaine 5 mg\u002Fkg in 250 ml of normal saline infused over 45 minutes.",[15],[25],"Xylocaine",{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"Diphenhydramine","Diphenhydramine 50 mg in 250 ml of normal saline infused over 45 minutes.",[9],[31],"Benadryl",[33],{"name":34,"affiliation":35,"role":36},"Dwight Moulin, Dr.","University of Western Ontario, Canada","PRINCIPAL_INVESTIGATOR",[38],{"facility":39,"status":11,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":11},"St. Joseph's Health Care","London","Ontario","N6A 4V2","Canada","CA",{"type":46,"coordinates":47},"Point",[48,49],-81.23304,42.98339,{"lat":49,"lon":48},{"type":52,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100183943","the-role-of-intravenous-iv-lidocaine-in-the-management-of-chronic-neuropathic-pain-of-peripheral-nerve-origin-100183943",false,"NCT01669967","The Role of Intravenous (IV) Lidocaine in the Management of Chronic Neuropathic Pain of Peripheral Nerve Origin","Inclusion Criteria:\n\n* Chronic neuropathic pain due to diabetes mellitus or herpes zoster and a score of 4\u002F10 or greater on the DN4 questionnaire.\n* Moderate to severe pain as defined by screening average pain intensity of 5 or greater on a 0-10 numerical rating scale.\n* Neuropathic pain duration of at least 6 months.\n\nExclusion Criteria:\n\n* Presence of clinically significant cardiac disease.\n* Poorly controlled seizure disorder.\n* Significant psychiatric disorder.\n* History of allergy to lidocaine or any other amide local anesthetic\n* History of allergy to diphenhydramine.\n* Prior treatment with a local anesthetic infusion.\n* Neuropathic pain due to cancer or complex regional pain syndrome\n* Language barrier or cognitive impairment that would preclude understanding of the study and filling out of questionnaires\n* Lack of a driver to transport the patient to and from the pain clinic.","ALL","18 Years","80 Years",{"count":63,"type":64},34,"ACTUAL","INTERVENTIONAL",[67],"NA","Pain as a result of nerve injury (neuropathic pain) is a particularly severe form of chronic pain. Common examples of neuropathic pain are pain due to diabetes and shingles. There is good evidence that an intravenous infusion of lidocaine (local anesthetic) is useful for the management of neuropathic pain in the short term - up to six hours.",[70],"Neuropathic Pain","COMPLETED","2019-03-13",{"date":74,"type":64},"2019-03-15",{"date":76,"type":11},"2011-09",{"date":78,"type":64},"2015-12",{"name":5,"class":6},1]